Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


28.08.2017

1 BMC Pediatr
1 J Immunol
33 J Infect Dis
4 JAMA
5 Lancet Infect Dis
2 MMWR Morb Mortal Wkly Rep
1 Pediatr Infect Dis J
1 Pediatrics
9 PLoS One
24 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Pediatr

  1. BLOMBERG K, Carlsson AA, Hagberg L, Jonsson O, et al
    Quality of life and trust among young people with narcolepsy and their families, after the Pandemrix(R) vaccination: protocol for a case-control study.
    BMC Pediatr. 2017;17:183.
    PubMed     Text format     Abstract available


    J Immunol

  2. JEYANATHAN M, Afkhami S, Khera A, Mandur T, et al
    CXCR3 Signaling Is Required for Restricted Homing of Parenteral Tuberculosis Vaccine-Induced T Cells to Both the Lung Parenchyma and Airway.
    J Immunol. 2017 Aug 21. pii: ji1700382. doi: 10.4049/jimmunol.1700382.
    PubMed     Text format     Abstract available


    J Infect Dis

  3. BILLAH MM, Zaman K, Estivariz CF, Snider CJ, et al
    Cold-Chain Adaptability During Introduction of Inactivated Polio Vaccine in Bangladesh, 2015.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  4. WASSILAK SGF, Williams CL, Murrill CS, Dahl BA, et al
    Using Acute Flaccid Paralysis Surveillance as a Platform for Vaccine-Preventable Disease Surveillance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  5. BA-NGUZ A, Adjagba A, Wisnu Hendrarto T, Sewankambo NK, et al
    The Role of National Immunization Technical Advisory Groups (NITAGs) in the Introduction of Inactivated Polio Vaccine: Experience of the Indonesia and Uganda NITAGs.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  6. BAHL S, Hasman A, Eltayeb AO, James Noble D, et al
    The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  7. TEVI-BENISSAN C, Okeibunor J, du Chatellier GM, Assefa A, et al
    Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  8. RAMIREZ GONZALEZ A, Farrell M, Menning L, Garon J, et al
    Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  9. OKAYASU H, Sein C, Chang Blanc D, Gonzalez AR, et al
    Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  10. SHENDALE S, Farrell M, Hampton LM, Harris JB, et al
    Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine-Lessons Learned.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  11. GURUNG S, Harris JB, Eltayeb AO, Hampton LM, et al
    Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  12. BLANKENHORN AL, Cernuschi T, Zaffran MJ
    Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  13. WANYOIKE S, Ramirez Gonzalez A, Dolan SB, Garon J, et al
    Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  14. RUBIN J, Ottosen A, Ghazieh A, Fournier-Caruana J, et al
    Managing the Planned Cessation of a Global Supply Market: Lessons Learned From the Global Cessation of the Trivalent Oral Poliovirus Vaccine Market.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  15. PREZA I, Subaiya S, Harris JB, Ehlman DC, et al
    Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  16. DECINA D, Fournier-Caruana J, Takane M, Ostad Ali Dehaghi R, et al
    Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  17. LEWIS I, Ottosen A, Rubin J, Blanc DC, et al
    A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  18. SCOTNEY S, Snidal S, Saidu Y, Ojumu A, et al
    Succeeding in New Vaccine Introduction: Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Cameroon, Kenya, and Nigeria.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  19. ONGWAE KM, Bawa SB, Shuaib F, Braka F, et al
    Use of Dedicated Mobile Teams and Polio Volunteer Community Mobilizers to Increase Access to Zero-Dose Oral Poliovirus Vaccine and Routine Childhood Immunizations in Settlements at High Risk for Polio Transmission in Northern Nigeria.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  20. OSADEBE LU, MacNeil A, Elmousaad H, Davis L, et al
    Assessing Inactivated Polio Vaccine Introduction and Utilization in Kano State, Nigeria, April-November 2015.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  21. DOLAN SB, Patel M, Hampton LM, Burnett E, et al
    Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  22. VERSCHOOR CP, Lelic A, Parsons R, Evelegh C, et al
    Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.
    J Infect Dis. 2017;216:191-197.
    PubMed     Text format     Abstract available

  23. HOLMES M, Abimbola T, Lusiana M, Pallas S, et al
    Resource Needs for the Trivalent Oral Polio to Bivalent Oral Polio Vaccine Switch in Indonesia.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  24. ZIPURSKY S, Patel M, Farrell M, Gonzalez AR, et al
    Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  25. NNADI C, Etsano A, Uba B, Ohuabunwo C, et al
    Approaches to Vaccination Among Populations in Areas of Conflict.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  26. WALLACE AS, Bohara R, Stewart S, Subedi G, et al
    Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  27. FAHMY K, Hampton LM, Langar H, Patel M, et al
    Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  28. THOMPSON KM, Duintjer Tebbens RJ
    Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  29. BURNETT E, Wannemuehler K, Ngoie Mwamba G, Yolande M, et al
    Individually Linked Household and Health Facility Vaccination Survey in 12 At-risk Districts in Kinshasa Province, Democratic Republic of Congo: Methods and Metadata.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  30. MENNING L, Garg G, Pokharel D, Thrush E, et al
    Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  31. MULDERS MN, Serhan F, Goodson JL, Icenogle J, et al
    Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  32. DIOP OM, Kew OM, de Gourville EM, Pallansch MA, et al
    The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  33. HAMPTON LM, du Chatellier GM, Fournier-Caruana J, Ottosen A, et al
    Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  34. THOMPSON KM, Duintjer Tebbens RJ
    Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available

  35. ESTIVARIZ CF, Snider CJ, Anand A, Hampton LM, et al
    Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    JAMA

  36. ABBASI J
    New Hope for a Gonorrhea Vaccine.
    JAMA. 2017 Aug 23. doi: 10.1001/jama.2017.11037.
    PubMed     Text format    

  37. SLOMSKI A
    Recombinant Influenza Vaccine More Effective in Older Adults.
    JAMA. 2017;318:690.
    PubMed     Text format    


  38. Vaccine Treatment Again.
    JAMA. 2017;318:758.
    PubMed     Text format    

  39. LYON J
    Vaccines Protect Fetus From Zika.
    JAMA. 2017;318:689.
    PubMed     Text format    


    Lancet Infect Dis

  40. STEELFISHER GK, Blendon RJ, Guirguis S, Lodge W 2nd, et al
    Understanding threats to polio vaccine commitment among caregivers in high-priority areas of Afghanistan: a polling study.
    Lancet Infect Dis. 2017 Aug 14. pii: S1473-3099(17)30397.
    PubMed     Text format     Abstract available

  41. O'REILLY KM
    Understanding commitment to polio vaccination.
    Lancet Infect Dis. 2017 Aug 14. pii: S1473-3099(17)30473.
    PubMed     Text format    

  42. SHEARER FM, Moyes CL, Pigott DM, Brady OJ, et al
    Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis.
    Lancet Infect Dis. 2017 Aug 16. pii: S1473-3099(17)30419.
    PubMed     Text format     Abstract available

  43. WILDER-SMITH A
    Yellow fever vaccination: estimating coverage.
    Lancet Infect Dis. 2017 Aug 16. pii: S1473-3099(17)30494.
    PubMed     Text format    

  44. DAMASO CR
    Revisiting Jenner's mysteries, the role of the Beaugency lymph in the evolutionary path of ancient smallpox vaccines.
    Lancet Infect Dis. 2017 Aug 18. pii: S1473-3099(17)30445.
    PubMed     Text format     Abstract available


    MMWR Morb Mortal Wkly Rep

  45. WALKER TY, Elam-Evans LD, Singleton JA, Yankey D, et al
    National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016.
    MMWR Morb Mortal Wkly Rep. 2017;66:874-882.
    PubMed     Text format     Abstract available

  46. MARTINEZ M, Shukla H, Nikulin J, Wadood MZ, et al
    Progress Toward Poliomyelitis Eradication - Afghanistan, January 2016-June 2017.
    MMWR Morb Mortal Wkly Rep. 2017;66:854-858.
    PubMed     Text format     Abstract available


    Pediatr Infect Dis J

  47. FIORITO TM, Baird GL, Alexander-Scott N, Bornschein S, et al
    Adverse Events Following Vaccination with Bivalent rLP2086 (Trumenba(R)): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review.
    Pediatr Infect Dis J. 2017 Aug 19. doi: 10.1097/INF.0000000000001742.
    PubMed     Text format     Abstract available


    Pediatrics

  48. VEERASINGAM P, Grant CC, Chelimo C, Philipson K, et al
    Vaccine Education During Pregnancy and Timeliness of Infant Immunization.
    Pediatrics. 2017 Aug 18. pii: e20163727. doi: 10.1542/peds.2016-3727.
    PubMed     Text format     Abstract available


    PLoS One

  49. WEISSMUELLER NT, Marsay L, Schiffter HA, Carlisle RC, et al
    Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine.
    PLoS One. 2017;12:e0183427.
    PubMed     Text format     Abstract available

  50. ZHANG A, Wang D, Li J, Gao F, et al
    The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity.
    PLoS One. 2017;12:e0183720.
    PubMed     Text format     Abstract available

  51. BODSON J, Wilson A, Warner EL, Kepka D, et al
    Religion and HPV vaccine-related awareness, knowledge, and receipt among insured women aged 18-26 in Utah.
    PLoS One. 2017;12:e0183725.
    PubMed     Text format     Abstract available

  52. KELLY HA, Ngou J, Chikandiwa A, Sawadogo B, et al
    Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa.
    PLoS One. 2017;12:e0174117.
    PubMed     Text format     Abstract available

  53. CALAZANS A, Boggiano C, Lindsay R
    A DNA inducing VLP vaccine designed for HIV and tested in mice.
    PLoS One. 2017;12:e0183803.
    PubMed     Text format     Abstract available

  54. VAN GOOR A, Stromberg ZR, Mellata M
    A recombinant multi-antigen vaccine with broad protection potential against avian pathogenic Escherichia coli.
    PLoS One. 2017;12:e0183929.
    PubMed     Text format     Abstract available

  55. KITTIKRAISAK W, Suntarattiwong P, Ditsungnoen D, Pallas SE, et al
    Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children </=60 months of age.
    PLoS One. 2017;12:e0183391.
    PubMed     Text format     Abstract available

  56. TAPIA F, Jordan I, Genzel Y, Reichl U, et al
    Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.
    PLoS One. 2017;12:e0182553.
    PubMed     Text format     Abstract available

  57. KUO CF, Tsao N, Hsieh IC, Lin YS, et al
    Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
    PLoS One. 2017;12:e0174464.
    PubMed     Text format     Abstract available


    Vaccine

  58. MCHUGH L, Andrews RM, Ware RS
    Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy 2012-2014: The FluMum study.
    Vaccine. 2017;35.
    PubMed     Text format    

  59. OHFUJI S, Okada K, Nakano T, Ito H, et al
    Control selection and confounding factors: A lesson from a Japanese case-control study to examine acellular pertussis vaccine effectiveness.
    Vaccine. 2017;35:4801-4805.
    PubMed     Text format     Abstract available

  60. FUKUSHIMA W, Hirota Y
    Basic principles of test-negative design in evaluating influenza vaccine effectiveness.
    Vaccine. 2017;35:4796-4800.
    PubMed     Text format     Abstract available

  61. HARA M, Hirota Y
    Basic principle of population-based cohort study to evaluate influenza vaccine effectiveness among elderly Japanese.
    Vaccine. 2017;35:4791-4795.
    PubMed     Text format     Abstract available

  62. HIROTA Y, Ozasa K, Nakano T
    Vaccine epidemiology: Its role in promoting sound immunization programs in Japan.
    Vaccine. 2017;35:4787-4790.
    PubMed     Text format     Abstract available

  63. EDELSTEIN M, Crocker-Buque T, Tsang C, Eugenio O, et al
    Extracting general practice data for timely vaccine coverage estimates: The England experience.
    Vaccine. 2017 Aug 16. pii: S0264-410X(17)31082.
    PubMed     Text format     Abstract available

  64. HUTCHEON J, Ortiz J
    Re: Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy 2012-2014: The FluMum study.
    Vaccine. 2017;35.
    PubMed     Text format    

  65. KONDO K, Suzuki K, Washio M, Ohfuji S, et al
    Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Vaccine. 2017;35:4806-4810.
    PubMed     Text format     Abstract available

  66. MORENO-MENDIETA S, Barrios-Payan J, Mata-Espinosa D, Sanchez S, et al
    Raw starch microparticles have immunostimulant activity in mice vaccinated with BCG and challenged with Mycobacterium tuberculosis.
    Vaccine. 2017 Aug 14. pii: S0264-410X(17)31079.
    PubMed     Text format     Abstract available

  67. CURCIO D, Cane A, Napuri N
    Comment on: Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analysis.
    Vaccine. 2017;35:4825.
    PubMed     Text format    

  68. KAUFMAN J, Ryan R, Lewin S, Bosch-Capblanch X, et al
    Identification of preliminary core outcome domains for communication about childhood vaccination: An online Delphi survey.
    Vaccine. 2017 Aug 20. pii: S0264-410X(17)31094.
    PubMed     Text format     Abstract available

  69. BEDFORD H, Attwell K, Danchin M, Marshall H, et al
    Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology.
    Vaccine. 2017 Aug 19. pii: S0264-410X(17)31070.
    PubMed     Text format     Abstract available

  70. LEVIN MJ, Buchwald UK, Gardner J, Martin J, et al
    Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Vaccine. 2017 Aug 19. pii: S0264-410X(17)31096.
    PubMed     Text format     Abstract available

  71. ATTWELL K, Smith DT
    Hearts, minds, nudges and shoves: (How) can we mobilise communities for vaccination in a marketised society?
    Vaccine. 2017 Aug 19. pii: S0264-410X(17)31072.
    PubMed     Text format    

  72. SIGURDSSON S, Erlendsdottir H, Quirk SJ, Kristjansson J, et al
    Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children.
    Vaccine. 2017 Aug 17. pii: S0264-410X(17)31087.
    PubMed     Text format     Abstract available

  73. JAYASUNDARA D, Hui BB, Regan DG, Heywood AE, et al
    Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia.
    Vaccine. 2017 Aug 17. pii: S0264-410X(17)31089.
    PubMed     Text format     Abstract available

  74. MISIAK A, Leuzzi R, Allen AC, Galletti B, et al
    Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
    Vaccine. 2017 Aug 17. pii: S0264-410X(17)31076.
    PubMed     Text format     Abstract available

  75. VILCA ML, Esposito S
    The crucial role of maternal care providers as vaccinators for pregnant women.
    Vaccine. 2017 Aug 16. pii: S0264-410X(17)31084.
    PubMed     Text format     Abstract available

  76. WORLD HEALTH ORGANIZATION
    Diphtheria vaccine: WHO position paper, August 2017 - Recommendations.
    Vaccine. 2017 Aug 16. pii: S0264-410X(17)31091.
    PubMed     Text format     Abstract available

  77. ZOLDI V, Sane J, Nohynek H, Virkki M, et al
    Decreased incidence of pertussis in young adults after the introduction of booster vaccine in military conscripts: Epidemiological analyses of pertussis in Finland, 1995-2015.
    Vaccine. 2017 Aug 17. pii: S0264-410X(17)31075.
    PubMed     Text format     Abstract available

  78. KUIPERS K, van Selm S, van Opzeeland F, Langereis JD, et al
    Genetic background impacts vaccine-induced reduction of pneumococcal colonization.
    Vaccine. 2017 Aug 16. pii: S0264-410X(17)31090.
    PubMed     Text format     Abstract available

  79. SINHA S, Kuo CY, Ho JK, White PJ, et al
    A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration.
    Vaccine. 2017 Aug 16. pii: S0264-410X(17)31081.
    PubMed     Text format     Abstract available

  80. PATERSON P, Chantler T, Larson HJ
    Reasons for non-vaccination: Parental vaccine hesitancy and the childhood influenza vaccination school pilot programme in England.
    Vaccine. 2017 Aug 14. pii: S0264-410X(17)31083.
    PubMed     Text format     Abstract available

  81. TOSCANO CM, Suarez V, Michel F, Bierrenbach AL, et al
    Response to comment on: Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses.
    Vaccine. 2017;35:4826-4827.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: